ENG Antibody

What is Endoglin (ENG/CD105) and why is it a significant target for antibody development?

Endoglin (CD105) is a 90 kDa type I transmembrane glycoprotein belonging to the zona pellucida (ZP) family of proteins. It functions as a co-receptor for the TGF-β family and is expressed on endothelial cells, activated macrophages, fibroblasts, and smooth muscle cells . ENG is significant for antibody development because:

• It's highly expressed during tumor angiogenesis and inflammation but shows weak expression in normal vascular endothelium

• It serves as a more specific and sensitive marker for tumor angiogenesis than CD31 or CD34

• It plays critical roles in cardiovascular development and vascular remodeling

• Its expression correlates with poor prognosis in several cancer types

• It exists in both membrane-bound and soluble forms (when cleaved by MMP14) , offering multiple targeting strategies

Methodologically, researchers should consider both the membrane-bound and soluble forms when designing detection or therapeutic strategies, as these forms may have distinct biological roles.

How is ENG expression regulated in normal versus pathological conditions?

ENG expression shows distinct patterns across normal and pathological states:

Normal conditions:

• Regulated during heart development

• Present at lower levels on hematopoietic, mesenchymal and neural crest stem cells

• Found on endothelial cells, particularly during proliferation

Pathological conditions:

• Significantly upregulated during tumor angiogenesis and inflammation

• Expression varies considerably across different cancer cell lines

• Can be epigenetically regulated - hypermethylation of CpG islands in the ENG promoter was observed in some Ewing sarcoma cell lines lacking ENG expression

• Often correlates with expression of MMP14, which cleaves membrane-bound ENG to produce soluble ENG

• Associated with poor prognosis in aggressive malignancies

When investigating ENG expression, researchers should employ multiple detection methods (qPCR, Western blotting, flow cytometry, and immunohistochemistry) to comprehensively characterize expression patterns across different contexts.

What approaches are most effective for generating high-affinity anti-ENG antibodies?

Multiple approaches have proven effective for generating high-affinity anti-ENG antibodies:

Traditional methods:

• Polyclonal antibody production in rabbits and larger mammals

• Mouse and rat hybridoma development involving immunization, B cell fusion with myeloma cells, and single-cell cloning

Modern approaches:

• Single B cell screening technologies for direct isolation of antibody-producing cells

• Phage display for screening large antibody libraries

• Hyperimmune mouse technology for generating diverse antibody repertoires

• Novel fusion protein approaches that stabilize protein complexes during immunization

For affinity optimization:

• Structure-based computational design when crystal structures are available

• Site-specific random mutagenesis targeting the complementarity determining regions (CDRs)

• In vitro evolution through display technologies

• Molecular engineering of variable domains

The choice of method depends on research goals, available resources, and whether the antibody is intended for research, diagnostic, or therapeutic applications.

How can researchers validate the specificity of anti-ENG antibodies?

Thorough validation of anti-ENG antibodies requires multiple complementary approaches:

Expression correlation:

• Test antibody binding across cell lines with varying ENG expression levels

• Confirm binding correlates with ENG mRNA and protein levels determined by qPCR and Western blot

Binding assays:

• Conduct concentration-dependent binding assays with recombinant human ENG

• Perform ELISA and flow cytometry analyses to determine binding affinity (OD50 and MFI50 values)

Cellular localization:

• Use immunocytochemistry to confirm proper membrane localization

• Compare with known patterns of ENG expression in various tissues

Knockout/knockdown controls:

• Include ENG-negative cell lines as negative controls (e.g., CADO cell line)

• Use siRNA/shRNA knockdown of ENG to confirm reduced antibody binding

Cross-reactivity testing:

• Evaluate binding to related proteins (like betaglycan/T beta RIII which shares 71% amino acid identity in transmembrane and cytoplasmic domains)

• Test species cross-reactivity if relevant for in vivo studies

Functional validation:

• Confirm internalization of the antibody in ENG-expressing cells

• Assess expected biological effects (e.g., inhibition of angiogenesis)

A comprehensive validation strategy increases confidence in experimental results and helps identify potential limitations of the antibody.

What are the challenges in predicting anti-ENG antibody structures?

Structure prediction for anti-ENG antibodies faces several significant challenges:

High variability in CDR loops:

• Complementarity determining regions (CDRs), especially CDR-H3, show substantial structural variability (RMSD values >2 Å) that cannot be captured by a single static structure

• This variability affects structure-based applications including antibody-antigen docking

Common modeling artifacts:

• Available antibody structure prediction tools (ABlooper, IgFold, DeepAb, Immunebuilder, MOE Antibody Modeler) can introduce structural inaccuracies

• These include cis-amide bonds in CDR loops, D-amino acids, and severe clashes, which can significantly influence biophysical property predictions

Structural validation requirements:

• Specialized tools like "TopModel" are needed to identify issues in protein structure models

• Additional validation is essential to increase prediction quality

Researchers should employ multiple prediction methods and carefully validate structural models before using them for further applications such as engineering or docking studies.

How are anti-ENG antibodies utilized in tumor angiogenesis research?

Anti-ENG antibodies serve multiple functions in tumor angiogenesis research:

As biomarkers:

• ENG is more specific for tumor angiogenesis than CD31 or CD34, labeling only newly-formed blood vessels

• Anti-ENG antibodies enable immunohistochemical assessment of tumor vascularization and prognostic evaluation in various cancers

For mechanistic studies:

• Investigate ENG's role in tumor angiogenesis and vasculogenic mimicry

• Study relationships between ENG expression, MMP14 levels, and soluble ENG production

In therapeutic development:

• Unconjugated anti-ENG monoclonal antibodies (e.g., TRC105) are being tested across diverse tumor types

• Anti-ENG antibody-drug conjugates (ADCs) like OMTX503 and OMTX703 have shown potent preclinical activity

For in vivo imaging:

• Labeled anti-ENG antibodies enable visualization of tumor angiogenesis

• Molecular engineering enhances antibody properties for this application

When designing angiogenesis studies, researchers should consider both tumor and stromal ENG expression, as the protein is present on both tumor cells and tumor-associated endothelial cells in many cancer types.

What advantages do anti-ENG antibody-drug conjugates offer over unconjugated antibodies in cancer therapy?

Anti-ENG antibody-drug conjugates (ADCs) provide several significant advantages over unconjugated antibodies:

Enhanced potency:

• ADCs combine antibody targeting specificity with cytotoxic drug payloads

• Studies with OMTX503 and OMTX703 demonstrated superior efficacy compared to unconjugated antibodies in suppressing cell proliferation and tumor growth

Targeted drug delivery:

• ADCs enable specific delivery of cytotoxic agents to ENG-expressing cells while minimizing systemic toxicity

• Internalization allows intracellular release and activation of payload moieties

Expression-dependent efficacy:

• Sensitivity to anti-ENG ADCs correlates positively with ENG expression levels

• Different cell lines showed varying IC50 values based on their ENG expression:

  • High expression: IC50 = 1.18×10^-10 M

  • Medium-low expression: IC50 = 9.155×10^-9 M

  • No expression: IC50 ≈ 1.738×10^-8 M

Dual targeting capability:

• ADCs can target both tumor cells expressing ENG and tumor vasculature

• This approach simultaneously addresses the tumor cells and their blood supply

Researchers developing anti-ENG ADCs should carefully consider payload selection, linker chemistry, and drug-to-antibody ratio to optimize efficacy while minimizing off-target effects.

How can anti-ENG antibodies be used to study vascular remodeling?

Anti-ENG antibodies provide valuable tools for investigating vascular remodeling processes:

Tracking endothelial activation:

• ENG expression is regulated during heart development and vascular remodeling

• Anti-ENG antibodies identify activated endothelial cells undergoing remodeling

Distinguishing vessel maturity:

• ENG marks newly formed blood vessels more specifically than other endothelial markers

• This specificity differentiates between established vasculature and areas of active remodeling

Investigating signaling mechanisms:

• ENG functions as a co-receptor for TGF-β family members crucial in vascular development

• Anti-ENG antibodies help elucidate how ENG modifies TGF-β family signaling

• ENG can inhibit TGF-β1 signals while enhancing BMP7 signals in the same cell type, suggesting complex regulation

Functional studies:

• Blocking antibodies assess the consequences of ENG inhibition on vascular processes

• Studies show anti-ENG antibody treatment can prevent liver sinusoidal endothelial cell inflammation and fibrosis progression

For comprehensive vascular remodeling studies, researchers should combine anti-ENG antibodies with other endothelial markers and functional assays to characterize both the structural and functional aspects of the remodeling process.

What role do anti-ENG antibodies play in preventing liver inflammation and fibrosis?

Recent research demonstrates important roles for anti-ENG antibodies in liver inflammation and fibrosis:

Targeting liver sinusoidal endothelial cells (LSECs):

• Anti-ENG antibodies (TRC105, M1043) bind to ENG on LSECs

• In a Metabolic Dysfunction Associated Steatohepatitis (MASH) animal model, anti-ENG antibody (M1043) treatment prevented LSEC inflammation and fibrosis progression

Molecular mechanisms:

• LSEC inflammation in MASH features overexpression of ENG, VCAM-1, and ICAM-1, with reduced VE-cadherin and p-eNOS/eNOS expression

• Anti-ENG antibody treatment prevented inflammatory marker overexpression

• Treatment also prevented liver fibrosis progression and liver-to-body weight ratio increase

In vitro confirmation:

• TRC105 experiments confirmed prevention of LSEC inflammation through reduced ENG and VCAM-1 expression

• Treatment decreased THP-1 monocytic cell adhesion in oxidized LDL-activated LSECs

Clinical implications:

• Directly targeting ENG represents a promising approach for addressing LSEC inflammation and liver fibrosis

• Anti-ENG antibodies could potentially be developed for treating inflammatory and fibrotic liver conditions

These findings suggest researchers should explore anti-ENG antibodies as potential therapeutics for liver diseases beyond their established role in cancer research.

What molecular engineering approaches can reduce immunogenicity of anti-ENG antibodies?

Several engineering approaches can minimize the immunogenicity of anti-ENG antibodies:

Humanization strategies:

• Chimeric antibodies: Fusion of murine variable domains to human constant regions

• CDR grafting: Transplanting only CDRs from murine antibody onto human framework

• Veneering: Modifying surface-exposed residues to resemble human antibodies

Structure-guided humanization:

• Crystal structure of antibody-antigen complex facilitates humanized variant design

• Helps identify critical positions outside CDRs that must be preserved

• Computational methods can predict and remove potentially immunogenic epitopes

Deimmunization:

• Targeted removal of T-cell epitopes that could trigger immune responses

• "Deimmunized" monoclonal antibodies have been evaluated clinically

• Example: ETI-204, a humanized and de-immunized antibody against Bacillus anthracis protective antigen

Species switching:

• Reformatting variable regions to a different species' antibody backbone

• Reduces immunogenicity and increases potency in animal models

• Prevents neutralizing antibody induction in the host organism

Fc engineering:

• Modifications to the Fc region reduce immunogenicity and alter effector functions

• Can improve pharmacokinetics and stability

When developing therapeutic anti-ENG antibodies, researchers should employ a combination of these approaches and validate reduced immunogenicity through in silico prediction, in vitro assays, and appropriate animal models.

How can bispecific antibodies targeting ENG be designed for improved therapeutic efficacy?

Designing effective bispecific antibodies (bsAbs) targeting ENG requires careful consideration of multiple factors:

Target selection for dual targeting:

• Pair ENG with complementary targets to enhance therapeutic outcomes

• Potential partners include:

  • Immune cell receptors (CD3, CD16) to recruit immune effectors

  • Other angiogenic markers (VEGFR) to target multiple angiogenic pathways

  • Tumor-associated antigens to enhance tumor specificity

Structural configuration:

• The configuration significantly impacts function and performance

• Options include:

  • IgG-like formats with dual Fab arms

  • Tandem scFv formats

  • Diabody formats

  • DVD-Ig (dual-variable-domain immunoglobulin) formats

Engineering for balanced binding:

• Ensure balanced affinity for both targets to prevent preferential binding

• Consider spatial arrangement to allow simultaneous engagement

Developability considerations:

• Engineer bsAbs with favorable developability profiles

• Address biophysical challenges including stability and aggregation propensity

The optimal design depends on the intended mechanism of action, target expression patterns, and required pharmacokinetic properties. Functional validation in appropriate models is essential to confirm therapeutic efficacy.

What strategies can enhance the internalization of anti-ENG antibodies for antibody-drug conjugate applications?

Enhancing internalization is crucial for antibody-drug conjugate efficacy. Several strategies can optimize anti-ENG antibody internalization:

Epitope targeting:

• Target epitopes involved in receptor-mediated endocytosis

• Structure-based design techniques can identify internalization-promoting epitopes

Molecular engineering:

• Site-specific mutagenesis or computational design can optimize internalization properties

• Modifications to framework regions or CDRs influence internalization efficiency

Leveraging natural trafficking:

• ENG undergoes endocytosis as part of TGF-β signaling

• Antibodies mimicking TGF-β binding might enhance internalization

Format optimization:

Fc engineering:

• Modifications to the Fc region influence receptor-mediated endocytosis

• Structure-based engineering can optimize these interactions

Studies with anti-ENG ADCs (OMTX503 and OMTX703) showed that high ENG expression correlates with efficient internalization and greater cytotoxicity , highlighting the importance of both target expression and antibody engineering for optimal ADC development.